Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach. Athera’s vision is to develop recombinant Annexin A5 for prevention of complications in patients with peripheral artery disease (PAD) undergoing vascular surgery. The project is currently in preclinical phase. PC-mAb from Athera is in late preclinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio.